| Bioactivity | Ralfinamide mesylate (FCE-26742A mesylate) is an orally available Na+ channel blocker derived from α-aminoamide, with function of suppressing pain[1][2]. |
| Target | Na+channel |
| In Vivo | Ralfinamide (30 mg/kg, 60 mg/kg; p.o.; twice daily; 42 days) treated with Ralfinamide (80 mg/kg; p.o.; twice daily; 7 days) preoperatively suppresses neuropathic pain[1]. Animal Model: |
| Name | Ralfinamide mesylate |
| CAS | 202825-45-4 |
| Formula | C18H23FN2O5S |
| Molar Mass | 398.45 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhang SH, et al. Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat. Pain. 2008 Oct 15;139(2):293-305. [2]. Liang X, et al. Effects of ralfinamide in models of nerve injury and chemotherapy-induced neuropathic pain. Eur J Pharmacol. 2018 Mar 15;823:27-34. |
Ralfinamide mesylate
CAS: 202825-45-4 F: C18H23FN2O5S W: 398.45
Ralfinamide mesylate (FCE-26742A mesylate) is an orally available Na+ channel blocker derived from α-aminoamide, with f
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.